Tags : PANTHERA trial

Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II

Shots: The P-I/II study involve assessing of pembrolizumab (IV, 200mg), Herzuma (biosimilar trastuzumab) (6mg/kg (after 8mg/kg load) D1 and CT in 43 patients with median follow up of 18 mons. In patients with HER2-positive advanced gastric cancer (AGC) P-I/II study results: tumor shrinkage of 95.3%, ORR of 76.7%, CR 16.3%, PR 60.5%, disease control rate […]Read More